In November 2019, a Dompé Market Access employee and a consultant exchanged information to determine how many patients prescribed the company’s drug, Oxervate, were pending at NORD, one of two foundations providing assistance. The consultant also analyzed foundation and specialty-pharmacy data when recommending donation budgets.
That account appears in Dompé’s settlement agreement with the Justice Department. It presents a concrete question: when information about patients needing help purchasing a manufacturer’s drug informs its donations, how independent is the funding process?
On September 10, DOJ announced a $32 million settlement resolving allegations that Dompé U.S. paid Medicare copays between 2018 and 2021 through two foundations, NORD and PANF, to induce purchases of Oxervate. Dompé admitted specified facts. There was no determination of liability.
The distinction matters. Manufacturer-supported charitable assistance can be appropriate. The concern is whether the manufacturer uses the arrangement to subsidize purchases of its own product.
Information Reached the People Recommending Donations
Dompé’s admissions describe contributions that sometimes increased midyear, with funds allocated to the foundations that were running low. Foundation and specialty-pharmacy data reached the Market Access team and people involved in contribution budgeting.
The November exchange provides the clearest connection. Information about pending Oxervate patients reached a consultant who made donation recommendations and used foundation and pharmacy data in that work.
Dompé also admitted that sales personnel obtained patient-specific foundation coverage information from patient access personnel, contrary to internal compliance guidance. See Recital F, paragraphs 4–6.
These facts describe more than a manufacturer making a donation and later discovering that some patients benefited. They connect information about assistance for the manufacturer’s product with the people recommending its funding.
The agreement does not quantify how much a particular recommendation changed because of that information. Nor does it provide a transaction-by-transaction account tracing each donation to a patient’s prescription. The useful lesson rests on the information flow the company admitted.
A Charity Can Help Patients Without Becoming a Conduit
The HHS Office of Inspector General’s guidance recognizes that properly structured charitable programs can help patients afford necessary treatment. It also warns against charities functioning as conduits for manufacturer payments to patients.
OIG examines whether donors influence the charity or its assistance decisions, whether disease funds are defined too narrowly, and whether a donor correlates contributions with assistance for its own products. A charity’s favorable advisory opinion does not automatically protect a manufacturer’s separate conduct.
That distinction explains why the source of funding alone does not settle the question. A manufacturer can support a charitable purpose. The regulatory concern grows when it can use information about demand for its drug to direct the amount or timing of assistance funding.
Consider a hypothetical donor that learns how many prescriptions for its product are waiting for copay support and calculates the contribution needed to enable those purchases. The charity may still process the applications, but the donor is financing a commercially defined result.
That illustration explains the concern. It is not a finding that Dompé calculated each donation in that exact way.
